Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
- Resource Type
- Article
- Source
- Lancet Respiratory Medicine; Jul2021, Vol. 9 Issue 7, p733-746, 14p
- Subject
CYSTIC fibrosis CYSTIC fibrosis transmembrane conductance regulator MEDICAL research - Language
- ISSN
- 22132600